Clinical Trial Update: Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of crizotinib in c-MET mutation endometrial cancer (metastatic/recurrent/persistent) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Endometrial Cancer Recurrent | Phase 2 | Status: TERMINATED